A phase <scp>III</scp> clinical trial of a mixture agent of plasma‐derived factor <scp>VII</scp>a and factor X (<scp>MC</scp>710) in haemophilia patients with inhibitors - Concepedia

Concepedia

Publication | Closed Access

A phase <scp>III</scp> clinical trial of a mixture agent of plasma‐derived factor <scp>VII</scp>a and factor X (<scp>MC</scp>710) in haemophilia patients with inhibitors

28

Citations

13

References

2016

Year

Yuichi Shinkoda, Akira Shirahata, Katsuyuki Fukutake, Junki Takamatsu, Midori Shima, Hideji Hanabusa, Hideo Mugishima, Hideyuki Takedani, Kazuo Kawasugi, M Taki,

Abstract

These results show that MC710 has sufficient haemostatic efficacy and safety, and can be used as a potential bypassing agent to control bleeding in haemophilia patients with inhibitors.

References

	Year	Citations

Page 1